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Genotype–Phenotype Correlations among
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Teresa Fu1, Sancy A. Leachman2, Neil J. Wilson3, Frances J.D. Smith3, Mary E. Schwartz4 and Jean Y. Tang1
Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder caused by mutations in four genes
(KRT6A, KRT6B, KRT16, or KRT17). The International PC Research Registry is a database with information on
patients’ symptoms as well as genotypes. We sought to describe the heterogeneity of clinical symptoms and
to investigate possible genotype–phenotype correlations in patients with two types of K16 mutations, p.Asn125
and p.Arg127, causing the PC-16 subtype of PC. We found that clinical symptoms depended on the type of
amino-acid substitution. Patients with p.Asn125Asp and p.Arg127Pro mutations exhibited more severe disease
than patients carrying p.Asn125Ser and p.Arg127Cys mutations in terms of age of onset of symptoms, extent of
nail involvement, and impact on daily quality of life. We speculate that amino-acid substitutions causing larger,
more disruptive changes to the K16 protein structure, such as a change in amino-acid charge in the p.Asn125Asp
mutation or a bulky proline substitution in the p.Arg127Pro mutation, may also lead to more severe disease
phenotypes. The variation in phenotypes seen with different substitutions at the same mutation site suggests a
genotype–phenotype correlation. Knowledge of the exact gene defect is likely to assist in predicting disease
prognosis and clinical management.
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INTRODUCTION
Pachyonychia congenita (PC; OMIM (Online Mendelian
Inheritance in Man) #167200 and #167210) is a rare,
autosomal dominant genetic disorder caused by mutations
in any one of four keratin (KRT) genes (KRT6A, KRT6B,
KRT16, and KRT17) encoding the keratin cytoskeletal
proteins K6a, K6b, K16, and K17, respectively (Smith et al.,
2005). Historically, K6a and K16 mutations have been
associated with PC-1 (Jadassohn-Lewandowski type) and
K6b and K17 mutations with PC-2 (Jackson-Lawler type)
(Smith et al., 2005). Recently, data from the International PC
Research Registry (IPCRR) have revealed considerable
phenotypic overlap between these subtypes; therefore, a
new molecular classification linking the mutant gene and
clinical subtype has been adopted (PC-6a, PC-16, and so on,
see Wilson et al., 2011).
In this study, we sought to characterize the clinical
characteristics of PC-16 patients with amino-acid substitutions
at two sites on the K16 protein, asparagine 125 (p.Asn125)
and arginine 127 (p.Arg127), which lie at the helix initiation
motif within the helix 1A domain (Steinert et al., 1993).
Previous studies have shown that mutations in this critical
area for keratin filament assembly can produce variable
clinical manifestations, suggesting a correlation between the
type of amino-acid substitution and severity of disease
(Shamsher et al., 1995; Covello et al., 1998; Smith et al.,
1999; Munro, 2001). However, these studies lacked the
numbers required to draw conclusions based on statistically
robust data.
Larger disruptions at the helix boundary motif sequences
have been shown to abrogate the normal assembly and
function of intermediate filaments (Smith et al., 1997, 1999).
Particularly disruptive changes may include bulky proline
substitutions such as p.Arg127Pro (Serrano et al., 1992) or
charge-associated changes from asparagine to aspartic acid,
as in p.Asn125Asp. We hypothesized that PC-16 patients
with more disruptive missense mutations, p.Asn125Asp and
p.Arg127Pro, would manifest more severe symptoms than
patients carrying their more conservative counterparts,
p.Asn125Ser and p.Arg127Cys.
RESULTS
As of June 2010, 72 individuals in the IPCRR had confirmed
K16 mutations; 34 had complete survey data. Of the 34
patients in this study, 100% reported focal plantar kerato-
derma, 29/34 (85%) reported some form of nail dystrophy,
and 16/34 (47%) reported oral leukokeratosis (Table 1).
Almost all patients (94%) reported some amount of plantar
pain; 74% had pain that was ‘‘very painful’’ or ‘‘painful
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enough to require medication.’’ Only two patients reported
steatocystomas, one reported pilosebaceous cysts, three
reported follicular hyperkeratosis, and none reported a
history of prenatal/natal teeth, similar to previous reports
(Leachman et al., 2005). In all, 20 individuals had mutations
at the Asn125 site and 14 had mutations at the Arg127 site.
Patients in each mutation group were compared against those
with different amino-acid substitutions at the same site; i.e.,
p.Asn125Asp versus p.Asn125Ser, and p.Arg127Pro versus
p.Arg127Cys.
Within the Asn125 group of patients, 4 patients had
p.Asn125Asp mutations, a potentially more disruptive change,
whereas 16 patients had the more conservative change
p.Asn125Ser. Interestingly, p.Asn125Asp patients had more
severe disease compared with p.Asn125Ser patients (Figure 1).
Patients with p.Asn125Asp mutations were more likely to have
8–10 thickened toenails (P¼0.006) and fingernails (P¼ 0.048)
beginning at an earlier age (1.3 vs. 13 years, P¼ 0.01 and 1.8
vs. 23 years, P¼ 0.06, respectively). All Asn125 patients
reported plantar keratoderma and most (70%) reported severe
Table 1. Demographics of and symptoms reported by PC-16 patients with one of four different mutations
Mutation groups
p.Asn125Asp
(n=4)
p.Asn125Ser
(n=16) P-value
p.Arg127Pro
(n=3)
p.Arg127Cys
(n=11) P-value
Demographic characteristics
Gender (% male) 100 56 0.11 67 55 0.73
Positive family history (%) 100 75 0.29 0 82 0.005
Number of families represented 1 8 3 5
Clinical findings and symptoms % (n) % (n) P-value % (n) % (n) P-value
Plantar symptoms
Persistent keratoderma1 100 (4) 100 (16) — 100 (3) 100 (11) —
Plantar pain2 100 (4) 63 (10) 0.18 100 (3) 73 (8) 0.31
Age of onset, plantar keratoderma, years (SD) 2.6 (0.8) 3.7 (2) 0.06 1.2 (0.8) 7.9 (4) o0.001
Thickened toenails, n (%)3
8–10 100 (4) 25 (4) 0.006 100 (3) 9 (1) 0.002
5–7 0 25 (4) 0 45 (5)
1–4 0 31 (5) 0 27 (3)
0 0 19 (3) 0 18 (2)
Age of onset, toenails, years (SD) 1.3 (2.5) 13 (13) 0.01 0.6 (0.4) 20 (19) 0.01
Palmar symptoms
Persistent keratoderma1 100 (4) 50 (8) 0.09 100 (3) 64 (7) 0.22
Palmar pain2 0 0 — 67 (2) 0 0.001
Age of onset, palmar keratoderma, years (SD) 4.6 (3) 11 (69) 0.06 1.2 (0.8) 11 (5.4) 0.001
Thickened fingernails, n (%)3
8–10 50 (2) 6 (1) 0.048 100 (3) 0 0.002
5–7 50 (2) 6 (1) 0 9 (1)
1–4 0 19 (3) 0 18 (2)
0 0 69 (11) 0 73 (8)
Age of onset, fingernails, years (SD) 1.8 (3.5) 23 (19) 0.06 0.6 (0.4) 28 (15) 0.09
Oral leukokeratosis 50 (2) 56 (9) 0.82 100 (3) 18 (2) 0.01
% Reporting severe impact on QOL4 50 (2) 19 (3) 0.20 100 (3) 9 (1) 0.002
Abbreviations: PC, pachyonychia congenita; QOL, quality of life.
1Comparing patients reporting persistence of keratoderma as ‘‘always’’ or ‘‘sometimes’’ to those answering ‘‘seldom’’ or ‘‘never.’’
2Comparing those reporting ‘‘very painful but no medication needed’’ or ‘‘often require medication for pain’’ to those answering ‘‘some pain’’ and ‘‘no pain.’’
3Comparing numbers of patients with 48 nails affected.
4Includes impact of affected toenails, fingernails, plantar keratoderma, and palmar keratoderma. Scores for answers of ‘‘always a problem’’ or ‘‘frequently impacts’’
were added; X2 of these responses¼ severe impact; 1¼mild impact, 0¼ little/no impact.
(—) P-values 40.05.
All P-values calculated using w2 or two-sided t-test where appropriate.
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plantar pain. Patients with p.Asn125Asp mutations had more
palmar keratoderma (P¼ 0.09) at an earlier age of onset (4.6 vs.
11 years, P¼0.06). There was more variability in palmar pain
and fingernail involvement (Table 1).
Of the 14 patients with mutations at the Arg127 site, 3 had
p.Arg127Pro mutations, the more disruptive substitution,
and 11 patients had p.Arg127Cys mutations. Patients with
p.Arg127Pro mutations were more likely to have 8–10
thickened toenails (P¼ 0.002) and fingernails (P¼0.002).
Although all patients reported persistent plantar keratoderma
and most (79%) reported plantar pain, p.Arg127Pro patients
were much more likely to report painful palmar keratoderma
(P¼0.001) and a significant impact on their quality of life
(P¼0.002). Interestingly, all p.Arg127Pro patients reported
oral leukokeratosis compared with 18% of p.Arg127Cys
patients (P¼ 0.01).
DISCUSSION
Most clinicians consider hypertrophic nail dystrophy the
dominant feature of PC. In our analysis, we found that most,
but not all, patients with K16 mutations exhibit nail
symptoms. Five patients reported no nail disease and all
had the milder p.Asn125Ser or p.Arg127Cys mutations,
consistent with one previous report (Shamsher et al., 1995).
All of our subjects reported persistent plantar keratoderma,
suggesting that this is not a distinguishing feature. A majority
(67%) also reported persistent palmar keratoderma, but
several patients with the milder mutations did not.
Although our sample size was limited, we found that PC
clinical symptoms depended on the type of amino-acid
substitution. p.Asn125Asp and p.Arg127Pro patients exhibited
more severe disease than their counterparts p.Asn125Ser and
p.Arg127Cys in terms of age of onset of symptoms, extent of
nail involvement, and impact on daily quality of life. In the
p.Asn125Asp mutation, asparagine, an uncharged amino acid,
is changed to aspartic acid, a negatively charged molecule. In
the p.Arg127Pro mutation, the change from arginine to proline
introduces a bulky proline side chain into the protein structure.
These changes in charge and protein structure may affect the
folding and function of the K16 filament. We speculate that
mutations causing these larger structural changes may lead to
more severe disease phenotypes and earlier age of onset.
Correspondingly, mutations involving relatively minor structur-
al changes at the same sites are associated with milder disease;
e.g., at the Asn125 site, patients with mutations from asparagine
to serine exhibited different, less severe disease characteristics
than those with asparagine to aspartic acid mutations. That
different mutations at the same site lead to different disease
phenotypes suggests a genotype–phenotype correlation. Inter-
estingly, we also found that symptoms varied within families
with identical mutations. In one family with four adult members
carrying the p.Asn125Asp mutation, two patients reported oral
leukokeratosis whereas two did not, suggesting that other
modifier effects may also be at play. Nevertheless, this study
emphasizes the importance of genotyping for clinical prognosis
and patient counseling. In the future, patients with mutations
causing severe disease may be ideal candidates for trials of
new, gene-targeted therapies for PC.
MATERIALS AND METHODS
In 2004, the IPCRR established an international registry for PC with
the goal of gathering patient data to improve understanding of the
p.Asn125Asp p.Asn125Ser
a
b
c
d
Figure 1. Comparing the extent of fingernail involvement and plantar keratoderma in patients with Asn125 site mutations in K16. (a, b) Patient carrying a
p.Asn125Asp mutation (more severe). (c, d) Patient carrying a p.Asn125Ser mutation (less severe).
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disease process and support investigation into potential therapies.
The registry was approved by the Western Institutional Review Board
(no. 20040468); more details on the survey and IPCRR can be found
online at www.pachyonychia.org. All subjects in the IPCRR
database underwent genetic testing, as previously described (Smith
et al., 2005). Sequencing of the KRT16 gene was performed on
genomic DNA from blood samples and confirmed using an
independent buccal DNA sample by GeneDx (Gaithersburg, MD).
Each subject received a standardized survey with questions on the
presence/absence and severity of PC clinical features, including
persistent plantar and palmar keratoderma, plantar and palmar pain,
thickened toenails and fingernails, and oral leukokeratosis (Table 1).
Subjects also answered questions regarding age of onset of each PC
symptom. For questions on severity of symptoms, answer choices
ranged from ‘‘never affected’’ to ‘‘always affected.’’ For questions
addressing presence of pain, answer choices ranged from ‘‘no pain’’
to ‘‘often require medication for pain.’’ Severity of nail disease was
assessed using absolute number of affected fingernails or toenails.
Impact of disease on quality of life was assessed by asking how often
symptoms affected daily life. Symptom severity, pain, and impact on
quality of life were assessed using a four-category Likert scale
(Table 1). Differences in proportions were analyzed with w2 tests and
continuous variables with two-sided t-tests. Statistical significance
was defined as Po0.05.
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